The management of individual patients requiring anthracyclines remains challenging
because uncertainty persists on predictors of cardiotoxicity. We aimed to perform a …

Importance Several studies have evaluated cardioprotective strategies to prevent
myocardial dysfunction in patients who are receiving cardiotoxic therapies. However, the …

Advances in oncologic therapies have led to considerable improvements in prognosis and
survival. However, these improvements may ultimately be diminished by the increase of …

Tremendous strides have been made in the treatment of various oncological diseases such
that patients are surviving longer and are having better quality of life. However, the success …

Anthracyclines are commonly used to treat childhood leukemias and lymphomas, as well as
other malignancies, leading to a growing population of long‐term childhood cancer …

Anthracycline chemotherapy causes dose-related cardiomyocyte injury and death leading to
left ventricular dysfunction. Clinical heart failure may ensue in up to 5% of high-risk patients …

Cancer incidence increases with age, and as life expectancy increases, the number of
elderly patients with cancer is increasing. Cancer treatments, including chemotherapy and …

Answer questions and earn CME/CNE Cancer and heart disease are the leading causes of
morbidity and mortality in the industrialized world. Modern treatment strategies have led to …

Anthracycline compounds are major culprits in chemotherapy-induced cardiotoxicity, which
is the chief limiting factor in delivering optimal chemotherapy to cancer patients. Although …

The spectrum of cardiac side-effects of cancer chemotherapy has expanded with the
development of combination, adjuvant and targeted chemotherapies. Their administration in …